Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

A. Yap, Timothy; Vidal, Laura; Adam, Jan; Stephens, Peter; Spicer, James; Shaw, Heather; Ang, Jooern; Temple, Graham; Bell, Susan; Shahidi, Mehdi; Uttenreuther-Fischer, Martina; Stopfer, Peter; Futreal, Andrew; Calvert, Hilary; S. de Bono, Johann; Plummer, Ruth

doi:10.1200/jco.2009.26.7278

Public

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Shared by NobleBlocks on Sep 1, 2010 • 12:00 AM UTC

Authors:

Timothy A. Yap

Laura Vidal

Jan Adam

Abstract

Purpose Preclinical data have demonstrated that BIBW 2992 is a potent irreversible inhibitor of ErbB1 (EGFR/HER1) and mutated ErbB1 receptors including the T790M variant, as well as ErbB2 (HER2). A phase I study of continuous once-daily oral BIBW 2992 was conducted to determine safety, maximum-toler...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!